tranilast and Cardiovascular-Diseases

tranilast has been researched along with Cardiovascular-Diseases* in 2 studies

Other Studies

2 other study(ies) available for tranilast and Cardiovascular-Diseases

Article	Year
SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications? European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:17 NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice. Topics: Betacoronavirus; Cardiovascular Diseases; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Cytokines; Humans; Inflammasomes; Myocarditis; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; ortho-Aminobenzoates; Pandemics; Pneumonia, Viral; Prognosis; SARS-CoV-2; Venous Thromboembolism	2020
PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH. International journal of cardiology, 2002, Volume: 83, Issue:2 Topics: Adult; Aged; Cardiovascular Diseases; Coronary Stenosis; Female; Heart Failure; Heart-Assist Devices; Humans; Hypolipidemic Agents; Male; Middle Aged; Multicenter Studies as Topic; ortho-Aminobenzoates; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Secondary Prevention; Sensitivity and Specificity; Treatment Outcome; Vitamins	2002

Article

Year

SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?

European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:17

NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.

Topics: Betacoronavirus; Cardiovascular Diseases; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Cytokines; Humans; Inflammasomes; Myocarditis; Nitriles; NLR Family, Pyrin Domain-Containing 3 Protein; ortho-Aminobenzoates; Pandemics; Pneumonia, Viral; Prognosis; SARS-CoV-2; Venous Thromboembolism

2020

PRESTO (a mammoth trial that could have been prevented), HPS and REMATCH.

International journal of cardiology, 2002, Volume: 83, Issue:2

Topics: Adult; Aged; Cardiovascular Diseases; Coronary Stenosis; Female; Heart Failure; Heart-Assist Devices; Humans; Hypolipidemic Agents; Male; Middle Aged; Multicenter Studies as Topic; ortho-Aminobenzoates; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Secondary Prevention; Sensitivity and Specificity; Treatment Outcome; Vitamins

2002